| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LHCGR |
| Uniprot No | P22888 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-363aa |
| 氨基酸序列 | EALCPEPCNCVPDGALRCPGPTAGLTRLSLAYLPVKVIPSQAFRGLNEVIKIEISQIDSLERIEANAFDNLLNLSEILIQNTKNLRYIEPGAFINLPRLKYLSICNTGIRKFPDVTKVFSSESNFILEICDNLHITTIPGNAFQGMNNESVTLKLYGNGFEEVQSHAFNGTTLTSLELKENVHLEKMHNGAFRGATGPKTLDISSTKLQALPSYGLESIQRLIATSSYSLKKLPSRETFVNLLEATLTYPSHCCAFRNLPTKEQNFSHSISENFSKQCESTVRKVNNKTLYSSMLAESELSGWDYEYGFCLPKTPRCAPEPDAFNPCEDIMGYDFLR |
| 预测分子量 | 41.6 Da |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LHCGR(黄体生成素/绒毛膜促性腺激素受体)重组蛋白的3-4篇代表性文献及其摘要内容：
1. **"Structure of the human luteinizing hormone-choriogonadotropin receptor complex"**
- **作者**: Zhang et al. (2019)
- **摘要**: 通过冷冻电镜技术解析了人源LHCGR与绒毛膜促性腺激素(hCG)结合的高分辨率结构，揭示了受体胞外域与配体结合的分子机制及跨膜区信号传导的激活模式。
2. **"Functional rescue of a naturally occurring LHCGR mutant reveals novel insights into ligand-induced receptor activation"**
- **作者**: Rivero-Müller et al. (2010)
- **摘要**: 利用重组LHCGR在HEK293细胞中的表达，研究了一种天然突变体(D405Y)的功能缺陷，发现其可通过外源性添加激素部分恢复信号活性，阐明了受体特定结构域在配体识别中的作用。
3. **"LHCGR-mediated endocytosis and signaling pathways in steroidogenesis"**
- **作者**: Ascoli et al. (2002)
- **摘要**: 探讨了重组LHCGR在介导激素内吞和下游cAMP/PKA信号通路中的关键作用，揭示了受体动态调控类固醇激素合成的分子机制。
4. **"Expression and purification of bioactive recombinant LHCGR extracellular domain in insect cells"**
- **作者**: Vu-Hai et al. (2004)
- **摘要**: 报道了一种在昆虫细胞(Sf9)中高效表达重组LHCGR胞外域的方法，并验证其与激素结合的特异性和生物活性，为结构研究和诊断试剂开发提供了技术支持。
以上文献涵盖了LHCGR的结构解析、功能机制、信号通路及重组表达技术等领域的研究进展。
The luteinizing hormone/choriogonadotropin receptor (LHCGR) is a G protein-coupled receptor (GPCR) critical for reproductive physiology. It binds luteinizing hormone (LH) and chorionic gonadotropin (hCG), hormones essential for regulating gonadal functions. In females, LHCGR activation triggers ovulation, corpus luteum formation, and progesterone production. In males, it stimulates testosterone synthesis in Leydig cells. Dysregulation of LHCGR is linked to infertility, polycystic ovary syndrome (PCOS), and reproductive cancers.
Recombinant LHCGR proteins are engineered to study receptor-ligand interactions, signaling mechanisms, and structural dynamics. These proteins are typically produced in mammalian (e.g., HEK293), insect (e.g., Sf9), or yeast expression systems to ensure proper post-translational modifications, such as glycosylation, which are vital for ligand binding and receptor activation. Purification often involves affinity tagging (e.g., FLAG, His-tag) and chromatography techniques.
Research applications include elucidating the structural basis of hormone-receptor specificity, identifying pathogenic mutations (e.g., familial male-limited precocious puberty), and developing therapeutic agents. Recombinant LHCGR also aids in drug screening for infertility treatments or antagonists to manage conditions like ovarian hyperstimulation syndrome. Additionally, it serves as a diagnostic tool for detecting autoantibodies in autoimmune reproductive disorders. By enabling precise biochemical and pharmacological studies, recombinant LHCGR advances both basic science and clinical innovations in reproductive health.
×
